

Insulin News, Reiterating our Commitment to Patients

You may have seen recent news that Eli Lilly plans to reduce the cost of its insulin products, including coverage in [NBC News](#) and the [Associated Press](#) that referenced Civica’s work. We want to take this opportunity to reiterate our commitment to bringing affordable insulins to people with diabetes across the country and to share Civica’s perspective on this news.

When we announced our transformational insulin pricing almost exactly a year ago, it was with the intent of making clear that there is a more affordable way to deliver these essential medicines to people with diabetes. With Lilly’s announcement, we are seeing them take a positive and commendable step in the right direction. At Civica we have always welcomed all efforts to address the current high price of insulin.

Civica’s plans are to produce three insulins – glargine, lispro and aspart (biologics corresponding to, and expected to be interchangeable with, Lantus®, Humalog® and Novolog®, respectively) – each of which will be available both in vials and prefilled pens. We plan to set a recommended price to the patient of no more than \$30 per vial and no more than \$55 for a box of five pre-filled pens.

Even following recent developments, Civica will be the only manufacturer offering all three insulins at low prices to patients.

We remain deeply committed to delivering lower-cost insulin, in addition to delivering a wide array of affordable medicines hospitals and consumers rely on every day. We are collaborating on this affordable insulin initiative with partners representing nearly every corner of the diabetes ecosystem, including the diabetes community, philanthropists, hospital systems, payers, clinical trial experts, drug substance manufacturers and leading pen and vial manufacturers.

Civica is in the late stages of building an [essential medicines manufacturing facility](#) in Petersburg, Virginia, to produce our insulin vials and prefilled pens for nationwide distribution, among a broad offering of sterile injectable medications used in hospitals for patient care, emergency room and intensive-care unit treatments, surgeries, and to treat other serious conditions.

We cannot predict what other manufacturers will do about pricing or supply, but we can say that Civica will supply all three affordable insulins to everyone.

When Civica was established in 2018, and CivicaScript soon after in 2020, we set out to make a difference by ensuring quality essential medicines are available and affordable to everyone.

We are doing what we set out to do:

- Bring true competition to the generic market, focusing on value (price and quality)
- Ensure stable and predictable supply of essential generic drugs, correcting shortages
- Be a conscience of the market, serving as a check against aggressive pricing behavior

From the beginning, we have said we are not entering medicine markets for “market share”...we are participating for “market impact.”

We are pleased to see that we, along with our many partners, are making a difference.